CardioSignal teams up with Roche Diagnostics to introduce a new innovative approach to heart disease detection
With this collaboration, CardioSignal’s motion sensor technology for heart disease detection is made available for healthcare professionals by combining it with Roche’s blood glucometer. The goal is to boost diagnostic performance, simplify clinical workflows, and improve patient outcomes by detecting often asymptomatic underlying heart conditions in everyday care.
Smart digital health technologies can enable a transformation of clinical workflows to point of care diagnostics while minimizing the burden to clinical staff. CardioSignal’s motion sensor technology allows for easy-to-use and reliable detection of atrial fibrillation with just one minute measurement when the device is placed on chest. As announced on January 12 by Roche Diagnostics, a global pioneer in pharmaceuticals and diagnostics, CardioSignal is now available through the recently launched cobas® pulse system, a glucometer for blood glucose monitoring. Cobas pulse, the next generation digital health technology by Roche Diagnostics, combines multiple health applications in one device.
Healthcare professionals performing everyday care of diabetes can now with one portable device screen for atrial fibrillation, and help identify individuals who are at increased risk of adverse health outcomes caused by undetected atrial fibrillation. Atrial fibrillation is the single most important cause of ischemic stroke.
There are several risk factors that significantly increase the risk of developing atrial fibrillation, such as hypertension, aging, and diabetes. According to studies, individuals with both atrial fibrillation and diabetes are less likely to notice heartbeat irregularities compared to people with atrial fibrillation and no diabetes.
“In everyday patient care, often asymptomatic and mild manifestations of atrial fibrillation may go undetected, as it has not been possible to screen every at-risk individual until now. Our goal with Roche is to integrate the latest technology into everyday medical practice that leads to early detection of cardiac diseases and improved outcomes. With cobas® pulse system being available in selected countries now and globally by 2023, this collaboration is a major step forward in making accessible and scalable heart health monitoring a reality,” says CEO, MD Juuso Blomster.
“Frontline health workers are under increasing pressure to not only accurately diagnose patients, but also make appropriate decisions on all aspects of disease management and patient care,” says Thomas Schinecker, CEO, Roche Diagnostics. “Our commitment is to equip them with high-performance innovations that represent a real step change in their working lives. We are pleased to introduce a truly novel solution that puts actionable clinical insights, and a near limitless range of digital capabilities for patient care, in the palms of their hands.”
At first, the CardioSignal technology enables efficient atrial fibrillation screening. Later, technological capabilities are expected to expand to other major heart diseases. Results from clinical multicenter studies in detection of heart failure and coronary artery disease are published later in 2022.
Further information:
CardioSignal
Juuso Blomster, CEO, juuso.blomster@cardiosignal.com
Juulia Simonen (Communications) juulia.simonen@cardiosignal.com, tel. +358503059018
About CardioSignal
We develop groundbreaking solutions for the detection of heart diseases. CardioSignal is a mobile application and a certified medical device for the detection of atrial fibrillation. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior. www.cardiosignal.com
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. www.roche.com.
Sources:
Association of Diabetes with Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study. Published 10 Nov 2021. Journal of the American Heart Association: https://www.ahajournals.org/doi/full/10.1161/JAHA.121.021800
